Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GeneWerk on the deal. GeneWerk announced its merger with Protagen Protein Services. GeneWerk, an Ampersand portfolio company, is a cell and gene therapy testing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised One GI on the deal. One GI announced its acquisition of Gastroenterology Health Partners, PLLC (GHP). The deal marks One GI’s sixth acquisition...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised One GI on the deal. One GI announced its acquisition of Gastroenterology Health Partners, PLLC (GHP). The deal marks One GI’s sixth acquisition...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised foreUP on the deal. Clubessential Holdings, the leading provider of membership and club-management solutions to the private club, college athletic, health and...
You must be a Standard 1 Year member to access this content.
